european end-to-end CDMO company, pharma services
  • About us
    • History
    • Leaderships
    • Team
    • EU grants
    • Requests for Proposal
    • Sustainability – ESG
    • Bussines strategy
    • Quality policy
    • Virtual Tour
  • Services
    • Drug Substance Manufacturing
    • Fill & Finish
    • Gene to Vial: End-to-End Development
    • Process Development
    • Analytics 
    • Cell Line Development & Banking
  • Science Hub
    • Science News
    • Resources
  • News & Events
    • Press releases
    • Events
    • Content to download
  • Investors
    • Corporate documents
    • Shareholders and shares
    • Periodic reports
    • Current reports
    • Sustainability reports
    • Corporate governance at Mabion
    • Financial data
    • For Investors
    • Calendar
  • Contact us
    • Contact form
    • Contact for investors
    • Contact for media
    • Careers
  • EN
  • Science News
  • Resources

Virus

Are mucosal vaccines the future of COVID-19 prevention?

2024-09-12
JN.1 variant of SARS-CoV-2 virus.

COVID-19 vaccine for 2024/25 season will target JN.1 variant

2024-05-14
Vaccine and syringe injection for prevention, immunization and treatment of coronavirus infection (COVID-19, nCoV 2019)

Effectiveness of 2023-24 season COVID vaccines: First estimates are in

2024-02-14

Moderna succeeds in the pivotal trial of RSV vaccine

2024-01-03

A new affordable HPV vaccine will help fight cervical cancer

2023-12-18

Researchers infect human volunteers with Zika virus in a quest for effective vaccine

2023-12-13

Contact

Find out how we may support your business.

bd@mabion.eu

Mabion

gen. Mariana Langiewicza 60
95-050 Konstantynów Łódzki
Poland

+48 42 207 78 90

    Mabion
    • Privacy policy
    • Services
    • Investors
    • News&Events
    • Contact us

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. Page Sitemap

    Powered by

    Veneo